Article Text

Download PDFPDF

Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q What is the potential of new generation antipsychotic drugs to improve adherence and decrease relapse rates in people with schizophrenia?


Embedded Image  Design:

Systematic review with meta-analysis.

Embedded Image  Data sources:

Medline (1996–April 2001), Current Contents (January 2001–May 2001) and the Cochrane Schizophrenia Group’s trial register (to July 2002); hand searches of bibliographies and contact with pharmaceutical companies.

Embedded Image  Study selection and analysis:

Randomised controlled trials, reporting on relapse rates and of ⩾6 months’ duration, comparing new generation antipsychotic drugs with placebo or conventional antipsychotics in people with schizophrenia or schizophrenia-like psychoses. Data were extracted on …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.